What is Windward Bio?
Windward Bio operates as a clinical-stage drug development enterprise dedicated to improving therapeutic outcomes for patients with advanced immunological and respiratory diseases. Led by a seasoned team of biopharmaceutical executives, the company integrates deep discovery expertise with commercialization strategy to bridge the gap between laboratory innovation and clinical application. Its core focus remains on developing best-in-class monoclonal antibodies and bispecific therapies that target the underlying mechanisms of chronic inflammation. By maintaining a rigorous focus on high-impact therapeutic areas, Windward Bio has established itself as a critical player in the next generation of immunology-focused biotech firms.
How much funding has Windward Bio raised?
Windward Bio has raised a total of $365M across 2 funding rounds:
Series A
$200M
Other Financing Round
$165M
Series A (2025): $200M with participation from SR One, Omega Funds Direct, Pivotal Bioventure Partners, Quan Capital, RTW Investments, Blue Owl Healthcare Communications, OrbiMed, Qiming Venture Partners, and Novo Holdings
Other Financing Round (2026): $165M led by SR One, Harbour BioMed, Qiming, Omega Alpha Spac, Quan Capital, RTW Investments, Pivotal Life Sciences Holdings, RA Capital Management, OrbiMed, Janus Henderson Investors, Blue Owl, Sanofi Ventures, and Novo Holdings
Key Investors in Windward Bio
SR One
SR One is a transatlantic biotechnology venture capital firm that invests in early and growth-stage life sciences companies developing novel therapeutics.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains.
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on long-term life science investments.
What's next for Windward Bio?
With the successful closure of its latest financing round, Windward Bio is poised to accelerate its clinical development timeline. The strategic priority for the coming quarters involves the execution of phase 2 trials for its lead TSLP monoclonal antibody, a program that represents a potential paradigm shift in respiratory disease management. Furthermore, the company intends to utilize these resources to scale its bispecific program pipeline, ensuring a robust and diversified research portfolio. As the firm transitions into this next phase of growth, it will continue to leverage its deep operational expertise and strategic partnerships to navigate the complexities of the global biopharmaceutical market, aiming for long-term value creation and improved patient outcomes.
See full Windward Bio company page
